IN8bio Reports Continued Progression-Free Survival in Phase 1 Investigator-Sponsored Trial of INB-100 Allogeneic Gamma-Delta T Cells for Leukemias at the 2024 American Society of Hematology Annual Meeting
10 déc. 2024 07h00 HE
|
IN8bio, Inc
IN8bio Reports Continued Progression-Free Survival in Phase 1 Trial of INB-100 Allogeneic Gamma-Delta T Cells for Leukemias at the 2024 ASH Conference
Biomea Fusion to Host Conference Call to Present initial Clinical Data from Phase I COVALENT-103 Study of BMF-500, a Covalent FLT3 Inhibitor, in Relapsed or Refractory Acute Leukemia
06 déc. 2024 08h00 HE
|
Biomea Fusion, Inc.
REDWOOD CITY, Calif., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral...
Aptose Signs CRADA with NCI to Develop Tuspetinib for AML and MDS in Newly Launched MyeloMATCH Precision Medicine Trials
03 déc. 2024 07h30 HE
|
Aptose Biosciences, Inc.
Aptose's AML drug tuspetinib selected for NCI's prestigious clinical research program for ability to target broad spectrum of AML and MDS populations
ImCheck to Present Encouraging Interim Results in AML Patients from the EVICTION Trial at the 66th American Society of Hematology Annual Meeting
26 nov. 2024 05h00 HE
|
ImCheck Therapeutics SAS
ImCheck to Present Encouraging Interim Results in AML Patients from the EVICTION Trial at the 66th American Society of Hematology Annual Meeting Marseille, France, November 26, 2024, 11 am CET –...
9-Year Old Rare Blood Disorder Survivor Meets Lifesaving Donor at Gift of Life Marrow Registry Gala
22 nov. 2024 15h37 HE
|
Gift of Life Marrow Registry
Miami Beach Event Honored Emilio Estefan, Jr., Vice Mayor Alex Fernandez and Boucher Brothers for their Distinguished Advocacy BOCA RATON, Fla., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Gift of Life...
First Patient Treated in Phase I/II Trial in Acute Myeloid and Acute Lymphoblastic Leukemia with Lu177-PentixaTher, Expanding the Evidence Base for Targeted Radiotherapy Approach
21 nov. 2024 05h07 HE
|
Pentixapharm Holding AG
BERLIN and WURZBURG, Germany, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Pentixapharm Holding AG, a biopharmaceutical company developing innovative first-in-class radiopharmaceuticals, today announced that...
Understanding the United States Chronic Lymphocytic Leukemia (CLL) Patient Journey to Make Informed Business Decisions, Identify Opportunities, and Understand Potential Challenges
25 oct. 2024 04h07 HE
|
Research and Markets
Dublin, Oct. 25, 2024 (GLOBE NEWSWIRE) -- The "Chronic Lymphocytic Leukemia (CLL) in the United States: Understanding the CLL Patient Experience" report has been added to ResearchAndMarkets.com's...
Understanding the United States Chronic Myeloid Leukemia (CML) Patient Experience to Make Informed Business Decisions, Identify Opportunities, and Understand Potential Challenges
25 oct. 2024 04h06 HE
|
Research and Markets
Dublin, Oct. 25, 2024 (GLOBE NEWSWIRE) -- The "Chronic Myeloid Leukemia (CML) in the United States: Understanding the CML Patient Experience" report has been added to ResearchAndMarkets.com's...
United States Chronic Myeloid Leukemia (CML) Patient Quality of Life & Information-Seeking Behaviors Insights Report 2024
24 oct. 2024 04h25 HE
|
Research and Markets
Dublin, Oct. 24, 2024 (GLOBE NEWSWIRE) -- The "Chronic Myeloid Leukemia (CML) in the United States: Quality of Life & Information-Seeking Behaviors" report has been added to ...
Smart Immune Announces Recommended SMART101 Dose for Adult Cancer Proof-of-Concept Trials
23 oct. 2024 01h01 HE
|
Smart Immune
ReSET-02 dose escalation Phase I is completedPhase II PoC randomized segment is starting No dose-limiting toxicities, no safety or tolerability issuesThe highest dose is to be used in both...